Genetic Polymorphism Screening for Anti-VEGF Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wet age-related macular degeneration (AMD) lack personalized approaches, as existing therapies do not effectively account for genetic polymorphisms that influence treatment efficacy and patient responsiveness, leading to variable outcomes.
Innovation Solution
Identification of specific genetic polymorphisms in the MMP25 and BATF genes, such as the rs1064875 and rs175714 alleles, to predict which patients with wet AMD are likely to benefit from high-affinity anti-VEGF antibody treatments, including the use of oligonucleotide kits for genotyping and amplification of these polymorphisms to tailor therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-VEGF antibody therapy is administered to all wet AMD patients, then treatment coverage is comprehensive, but treatment efficacy varies due to genetic polymorphism differences among patients
Solution Approach 1:
The patent applies local quality by identifying specific genetic polymorphisms (MMP25 rs1064875 and BATF rs175714) that determine differential treatment responses in specific patient subgroups. Rather than uniform treatment, the therapy is adapted to local genetic characteristics, where patients with AA or AG genotypes receive anti-VEGF antibodies while those with GG genotypes do not, optimizing efficacy for each genetic subgroup
Solution Approach 2:
The patent changes the treatment parameter from a binary administer/don't administer decision to a genotype-stratified approach. By using genetic polymorphism status as a stratification parameter, the treatment regimen is customized based on molecular characteristics, transforming standard therapy into personalized medicine that accounts for inter-patient genetic variability
2Adaptability or versatility
If genetic screening for MMP25 and BATF polymorphisms is performed before treatment, then personalized treatment selection is enabled, but additional testing time and complexity are required
Solution Approach 1:
The patent segments the complex task of personalized treatment selection into discrete, manageable components: specific SNP genotyping for MMP25 (rs1064875) and BATF (rs175714) genes. By focusing on these two specific genetic markers rather than comprehensive genomic analysis, the assay complexity is reduced while maintaining predictive accuracy for treatment response
Solution Approach 2:
The patent introduces genetic polymorphism status as an intermediary marker that mediates between patient characteristics and treatment selection. Rather than directly assessing treatment response or disease severity, the genotype serves as a surrogate intermediary that predicts which patients will benefit from anti-VEGF antibodies, simplifying the decision-making process
3Reliability
If genetic polymorphism screening is implemented to identify suitable candidates, then treatment outcomes are improved, but loss of time for screening and genotyping occurs
Solution Approach 1:
The patent applies preliminary action by performing genetic screening and genotyping before treatment initiation. By determining MMP25 and BATF genotype status in advance, the system identifies suitable candidates for anti-VEGF antibody therapy before treatment begins, ensuring that only patients with AA or AG genotypes receive the therapy, thereby optimizing outcomes from the outset
Data Source
Figure 1
AI summary
The application relates to methods for determining whether a patient is at increased risk of developing wet AMD or whether a patient has an increased likelihood of benefiting from treatment with a high-affinity anti-VEGF antibody.